A5084314819- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune and Inflammatory Disorders Research
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Systemic Lupus Erythematosus Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Medical and Biological Sciences
- Cytokine Signaling Pathways and Interactions
- Inflammatory Bowel Disease
- Inflammatory mediators and NSAID effects
- Biochemical and Molecular Research
- Research on Leishmaniasis Studies
- Sarcoidosis and Beryllium Toxicity Research
- Osteoarthritis Treatment and Mechanisms
- Chemical synthesis and pharmacological studies
- Adenosine and Purinergic Signaling
- Microscopic Colitis
- Natural product bioactivities and synthesis
- Blood groups and transfusion
- Liver Diseases and Immunity
- Acute Lymphoblastic Leukemia research
- Flavonoids in Medical Research
City Clinical Hospital
2017-2024
Belarusian Medical Academy of Post-Graduate Education
2018-2022
Clinical Hospital No. 8
2018-2021
City Clinical Hospital No 31
2016-2020
Vitebsk State Medical University
2008
The article considers the results of an international multicenter randomized clinical trial efficacy and safety brand-name drug rituximab (MabThera), a monoclonal antibody against CD20 antigen B cells, its biosimi-lar (Acellbia®) (the BIORA study) in patients with rheumatoid arthritis (RA) refractory to therapy tumor necrosis factor- а inhibitors. Objective: provide evidence for therapeutic equivalence Acellbia® MabThera® also assess their interchangeability. Subjects methods. enrolled adult...
The article presents the results of three-year use netakimab (NTK) in patients with ankylosing spondylitis (AS) as part phase III BCD-085-5/ASTERA study. Objective : to evaluate long-term efficacy and safety NTK over a period active AS. Material methods . – double-blind, multicenter, randomized clinical trial that enrolled AS (BASDAI ≥4) back pain intensity ≥4 on numeric rating scale inefficacy or intolerance non-steroidal anti-inflammatory drugs biologic drugs. A total 228 were 1:1 ratio...
Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of AURORA phase II study. Objective : to evaluate efficacy safety and immunogenicity LVL in methotrexate (MTX) resistant patients with active rheumatoid arthritis (RA). Materials methods . 105 RA were randomized 1:1:1 ratio into two or placebo groups. was administered subcutaneously at dose 162 mg every week (QW) other (Q2W). All received MTX. After...
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A. Objective . The main objective of BCD-085-5/ASTERA study was to prove superiority NTK over placebo and assess its’ safety in patients with active AS. Subjects methods double-blind, multicenter, randomized, placebo-controlled, phase III study, which included 228 adult AS, persisting despite treatment NSAIDs. AS considered at BASDAI score ≥ 4.0. Patients were blindly randomized (1:1) receive subcutaneous injections...
Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives data obtained during 52-week follow-up of AS patients in phase III ASTERA study. Objective : study efficacy safety NTK when used long with active AS. Patients methods . investigation enrolled 228 AS, whom nonsteroidal anti-inflammatory drugs or biological agents were ineffective....
DNase autoantibodies (Abs) can be found in the blood of patients with several autoimmune diseases, while healthy donors or diseases insignificant disturbances immune status does not contain Abs. Here we have analysed for first time activity caused by bacterial infections. Several rigid criteria been applied to show that is an intrinsic property IgGs from sera but donors. The relative has shown vary extensively between and patient patient, most preparations had detectable levels activity. On...
Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study. Objective : to confirm efficacy and safety levilimab in combination with methotrexate (MTX) patients resistant active rheumatoid arthritis (RA). Patients methods . 154 adult patients, aged ≥18 years diagnosis RA (ACR/EULAR 2010) confirmed disease activity at screening despite treatment MTX for least 12 (in a stable dose 15-25 mg/week). were...
<h3>Background</h3> BCD-085 is an innovative humanised monoclonal antibody against interleukin-17 with genetically modified Fc- and CDR-regions, aimed to improve treatment outcomes in patients several autoimmune disorders. <h3>Objectives</h3> This abstract presents the results of double-blind placebo controlled dose-finding phase II clinical study efficacy safety subcutaneous ankylosing spondylitis. <h3>Methods</h3> The was conducted as international multicenter randomised study. enrolled 88...
The article contains the data obtained during 156-week follow-up of patients with ankylosing spondylitis (AS) in ASTERA phase III study. Objective : to evaluate effect impact netakimab (NTK) on quality life (QoL), back pain and work capacity active AS. Material methods . study enrolled 228 AS who were randomized 1:1 receive NTK 120 mg or placebo. At week 52, Group 1 achieved ASAS20 continued therapy (NTK at a dose once every 2 weeks) until 156. Patients (placebo/NTK) received drug...
Научно-практическая ревматология.2019;57(6):668-677 О р и г н а л ь ы е с д о в я 1 ФГБНУ «Научно-исследовательский институт ревматологии им.В.А.Насоновой», Москва, Россия; 2 ФГБОУ ВО «Северо-Западный государственный медицинский университет им.И.И.Мечникова» Минздрава России, Санкт-Петербург, 3 «Казанский университет» Казань, 4 ГАУЗ НСО «Городская клиническая поликлиника №1», Новосибирск, 5 НУЗ «Отделенческая больница на станции Смоленск ОАО «РЖД», Смоленск, 6 ГБУЗ НО «Нижегородская...
The paper gives data on the clinical efficiency and safety profile of long-term use infliximab (INF) biosimilar BCD-055 versus reference drug Remicade® (REM) in a population patients with active ankylosing spondylitis (AS). Subjects methods . An international multicenter randomized double-blind Phase III trial was conducted 199 who were into two groups 2:1 ratio received or REM at dose 5 mg/kg 0, 2, 6 weeks, then every 8 weeks. Efficiency assessment made 14, 30 54 weeks least one INF...
<h3>Background</h3> Infliximab (IFX) was one of the first genetically engineered biologics successfully applied for medical use in patients with active RA and AS. Previous preclinical studies showed that BCD-055 is highly similar to innovator IFX. <h3>Objectives</h3> This abstract presents results from three clinical trials infliximab biosimilar, BCD-055, including comparative data on pharmacokinetics (PK), efficacy safety a variety patient populations. <h3>Methods</h3> All were conducted as...
<h3>Background</h3> Equivalent efficacy of BCD-055 and infliximab (INF) innovator has been previously established (the primary endpoint: ACR20 at Wk14)<sup>1</sup>. <h3>Objectives</h3> The impact INF on RA activity analysed within 14 week study period. DAS28-CRP(,<sup>4</sup> CDAI SDAI were evaluated. Additionally, safety data collected. <h3>Methods</h3> was conducted as international multicenter randomised double-blind placebo controlled study. enrolled 426 adults with active RA. Patients...
A group of 266 patients with spondyloarthritidis and 69 healthy persons were included in our study. IgG preparations isolated from blood sera by a combined rivanol/affine chromatography technique. Homogeneity IgGs was tested means SDS-PAGE. Serum samples persons, subclasses 1, 2 4 for DNAse activity. method activity measurement based on rivanol capacity to form clot DNA. We have found highly significant differences between the levels associated spondyloarthritidis, donors (p < 0,0001)....
<h3>Background</h3> Non-inferiority of BCD-055 in direct comparison to infliximab originator after 30 weeks treatment patients with ankylosing spondylitis (AS) was shown previously<sup>1</sup>. Here we present 54 week safety and efficacy data ITT population from international double-blind randomised ASART-2 clinical trial. <h3>Objectives</h3> To compare BCD-055, proposed biosimilar terms AS. <h3>Methods</h3> Adult (n=199) aged 18–65 years, active AS (BASDAI>4) received 5 mg/kg (n=132) or...
Polyclonal immunoglobulins G (subclasses 1, 2, 4) from sera of 255 patients and 69 healthy persons were studied by a combined approach using rivanol treatment affinity chromatography. Enzymatic reactions carried out according to the methods that we have previously developed validated for evaluation abzyme activity in with different disorders. The levels DNase, proteolytic BAPNA-amidase (benzoylarginine-p-nitroanilide amidase), superoxyde dismutase spondyloarthropathies proved be...
Резюме.